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Abstract Between 2002 and 2008, a number of consen-
sus statements and guidelines were developed by various
groups around the world to educate healthcare profes-
sionals on the treatment of myelodysplastic syndromes
(MDS), including the management of transfusional iron
overload with iron chelation therapy. Guidelines have been
developed by The Italian Society of Hematology, The UK
MDS Guidelines Group, The Nagasaki Group, The
National Comprehensive Cancer Network, and The MDS
Foundation. These guidelines show that the approaches to
managing iron overload in patients with MDS are region
speciﬁc, differing in their recommendations for when iron
chelation therapy should be initiated and strategies for the
ongoing management of iron overload. The guidelines all
agree that red blood cell transfusions are clinically bene-
ﬁcial to treat the symptomatic anemia in MDS, and that
patients with low-risk MDS receiving transfusions are the
most likely to beneﬁt from iron chelation therapy.
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1 Introduction
Although the myelodysplastic syndromes (MDS) are a
relatively rare condition, the incidence in the general
population is similar across the world: about ﬁve per
100,000 persons per year. Incidence is linked with age,
rising to 20–50 per 100,000 persons per year in patients
older than 60 years of age, and a median age at diagnosis
of between 60 and 75 years [1–3] In Japan, the median age
of diagnosis of MDS is 57 years, younger than in Cauca-
sian patients [4].
Recent developments in the treatment of MDS, and
growing evidence of the effects of iron overload on mor-
bidity and mortality, have warranted the development of
guidelines to inform physicians on the best available, most
current treatment strategies for the management of iron
overload [5, 6]. Between 2002 and 2008, a number of
consensus statements and guidelines were developed by
different groups around the world to educate healthcare
professionals on the management of MDS. Although there
are limited data on the clinical consequences of iron
overload in patients with MDS, the guidelines also discuss
management of transfusional iron overload as an important
component of treating MDS, and also consider the clinical
consequences of iron overload, the need to monitor patients
who may be at risk of iron overload, and the need to treat
iron-overloaded patients. The approaches to treating iron
overload are likely to be region speciﬁc, so it is important
that healthcare professionals treating transfusion-dependent
patients with MDS are aware of best practice in their
country.
The guidelines that have been developed include those
of The Italian Society of Hematology [7], The UK MDS
Guidelines Group [8], The Nagasaki Group, and The
National Comprehensive Cancer Network (NCCN) in the
USA [9]. This review will summarize the content of these
guidelines, comparing relevant factors that inﬂuence the
diagnosis and treatment of transfusion-dependent, iron-
overloaded patients with MDS, including the classiﬁcation
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DOI 10.1007/s12185-008-0118-zsystems used, recommendations for supportive therapy,
and management of iron overload with the available iron
chelation therapies. The MDS Foundation has also pre-
pared a set of guidelines, with publication anticipated in
2008 [10].
2 Overview of the available guidelines
2.1 The Italian Society of Hematology
In 2001 and 2002, the Italian Society of Hematology
commissioned a series of consensus conferences to provide
clinical practice recommendations to support the appro-
priate choice of therapeutic interventions in patients with
primary MDS, both of adult and pediatric age [7]. This led
to the development of guidelines for the treatment of MDS
using evidence-based knowledge and consensus-formation
techniques. The guidelines were compiled by an expert
panel of ten senior hematologists, and cover therapeutic
options for MDS and supportive therapies including iron
chelation, with statements graded according to the strength
of the supporting evidence. The guidelines cover topics
such as which patients are candidates for treatment, the
appropriateness of new therapies, and optimizing transfu-
sion and iron chelation therapy.
2.2 The UK MDS Guidelines Group
The UK guidelines group, which published their ﬁndings in
2003, included UK-based medical experts in the clinical
management of MDS as well as a representative from a
District General Hospital [8]. The drafting group met on six
occasions, and no recommendations were included without
a full consensus. The guidelines cover diagnosis of MDS,
classiﬁcation, the various prognostic scoring systems, and
management of MDS.
2.3 The Nagasaki Group
A group of leading hematologists meeting in 2005 in
Nagasaki, Japan, were the ﬁrst to develop a consensus
statement on the treatment of iron overload in patients with
MDS. The main session was followed by regional discus-
sion groups, and a ﬁnal discussion on the consensus
statement. They discussed fundamental questions such as
which cases of MDS should be treated, when it is necessary
to initiate treatment, and strategies for the treatment of
iron-overloaded patients in continents around the world
[11]. The group included healthcare professionals from
Asia-Paciﬁc (n = 13), Europe (n = 13), and Latin Amer-
ica (n = 8). The meeting summarized the current practice
within each region and developed a consensus statement on
the treatment of iron overload in patients with MDS that
covers the knowledge at the time.
2.4 The National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN) is
an alliance of 21 leading cancer centers, developing
treatment guidelines for most cancers to improve the
quality and effectiveness of care provided to patients. Each
set of guidelines is a comprehensive set of diagnostic,
treatment and supportive care recommendations. The
guidelines for MDS are a statement of consensus devel-
oped by the NCCN Myelodysplastic Panel members and
are reviewed annually. They include algorithms that cover
the initial evaluation of MDS, the classiﬁcation systems for
de novo MDS, different treatment strategies for each
International Prognostic Scoring System (IPSS) category,
evaluation and treatment of the related anemia, as well as
supportive therapy [9]. Among other therapeutic options
covered by the guidelines, the panel recommends man-
agement of iron overload resulting from supportive
transfusions with iron chelation therapy. This is discussed
in greater detail below.
2.5 The MDS Foundation
The MDS Foundation has developed a set of consensus
guidelines for the management of iron overload in patients
with MDS. The guidelines are the result of discussions that
took place during a series of 20 international round-table
meetings. The guidelines were ﬁnalized at the MDS con-
gress held in Florence, Italy, in May 2007, and are
expected to be published in 2008. The main conclusions
from the guidelines were presented at the MDS congress
and are summarized here [10].
2.6 Japanese Guidelines for the treatment of
transfusional iron overload (National Research
Group on Idiopathic Bone Marrow Failure
Syndromes)
Most recently, a group of Japanese physicians also con-
vened at the MDS congress in Florence in 2007 to develop
guidelines for the treatment of iron overload in bone-
marrow failure in Japan, and to align Japanese and inter-
national guidelines. The group discussed which patients
would most beneﬁt from iron chelation therapy, diagnosis
of iron overload, when to initiate iron chelation therapy,
classiﬁcation of severity of iron overload, and monitoring
and maintaining iron chelation therapy. These guidelines
are discussed in further detail in the accompanying man-
uscript by Dr Ozawa.
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3.1 The classiﬁcation of MDS
In order to initiate iron chelation therapy appropriately, an
understanding of the various classiﬁcation systems is
required. Understanding the prognosis of the MDS sub-
groups is equally important for the treatment of iron
overload. MDS is a heterogeneous disease and two clas-
siﬁcation systems have been developed to classify the
various subgroups. The French-American-British (FAB)
system, developed in 1976 and revised in 1982, divided
MDS patients into ﬁve subtypes: refractory anemia (RA),
refractory anemia with ringed sideroblasts (RARS),
refractory anemia with excess blasts (RAEB), refractory
anemia with excess blasts in transformation (RAEB-T) and
chronic myelomonocytic leukemia (CMML) [12]. The
FAB system served as the gold standard for MDS classi-
ﬁcation for many years.
The World Health Organization (WHO) developed its
system in 2002, incorporating many of the concepts and
deﬁnitions of the FAB system, and adding refractory
cytopenia with multilineage dysplasia (RCMD), refractory
cytopenia with multilineage dysplasia and ringed sidero-
blasts (RCMD-RS), unclassiﬁed myelodysplastic syndrome
(MDS-U) and eliminating RAEB-T and CMML. 5q-syn-
drome, commonly seen in older women with normal or
high platelet counts, was considered to be a separate sub-
type, creating a total of eight subtypes [13]. The 5q-
syndrome, RA and RARS subtypes are associated with the
best survival rates, and RAEB II is associated with the
worst (Fig. 1)[ 14].
The IPSS, introduced in 1997, improved on the MDS
classiﬁcation systems by introducing an assessment of the
chances of overall survival and risk of transformation to
acute myeloid leukemia for individual patients [15]. The
IPSS uses a consensus-based approach for evaluating
prognosis in MDS and is used in conjunction with the
WHO and FAB diagnostic systems. The critical prognostic
features of MDS were identiﬁed as the proportion of bone
marrow blasts, the karyotype and the presence of one or
more cytopenias (Table 1)[ 15].
Not discussed within any of these guidelines is a new
prognostic classiﬁcation system, the WPSS, which was
conceived in 2007 by combining the WHO and IPSS sys-
tems. While the IPSS assesses prognosis of untreated
patients at the time of diagnosis, the WPSS can also be
used thereafter to assess risk during the course of a
patient’s disease [16].
All the guidelines discussed within this review recom-
mend the use of the IPSS, which they agree is useful for the
prognostic stratiﬁcation of MDS. When the UK MDS
guidelines were published, the WHO system had only
recently been published and there had been only limited
experience with this; therefore, the more familiar FAB
system was used [8]. The expert panel preparing the Italian
guidelines chose to adopt the WHO classiﬁcation system
and the IPSS risk scores, dispensing with the FAB-classi-
ﬁed RAEB-T subgroup [7]. The NCCN guidelines state
that the IPSS has markedly improved the prognostic
stratiﬁcation of MDS, and endorse both the FAB and WHO
classiﬁcation systems, noting that the RAEB-T subgroup
may be considered for either MDS or AML [9]. The
Nagasaki group report that the WHO system is the most
commonly used worldwide, although the FAB system is
still commonly used in Europe and Latin America [11].
Fig. 1 Survival of patients with MDS according to the WHO criteria
[14]. Reprinted from Germing U et al. Haematologica 2006;91:1596–
1604. With kind permission of the Ferrata Storti Foundation, Pavia,
Italy
Table 1 The IPSS system
Prognostic variable Score
0 0.5 1.0 1.5 2.0
Bone marrow blasts (%) \5 5–10 – 11–20 21–30
Cytogenetics Good Intermediate Poor
Cytopenias 0/1 2/3
Score IPSS subgroup Median survival (years)
0 Low 5.7
0.5–1.0 Int–1 3.5
1.5–2.0 Int-2 1.2
[2.5 High 0.4
This research was originally published in [15]. Greenberg P et al.
Blood 1997;89:2079–88.
The American Society of Hematology
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estimate prognosis, particularly in Europe and Asia-Paciﬁc,
as well as by about 50% of hematologists in Latin America.
3.2 Supportive therapy for MDS
Supportive care, which includes red blood cell (RBC)
transfusions, improves patient quality of life and remains
the mainstay of treatment for MDS [9]. All the guidelines
highlight the importance of supportive therapy and rec-
ommend RBC transfusions for symptomatic anemia as
needed. The NCCN guidelines also suggest platelet trans-
fusions for patients with severe thrombocytopenia or
thrombocytopenic bleeding.
The guidelines differ on their recommendations for the
hemoglobin (Hb) level at which transfusions should be
initiated, and recommend taking into account issues such as
quality of life, improved oxygenation and cardiac function,
as well as risks of infection and iron overload. The Italian
Society of Hematology guidelines indicate that all patients
with Hb\8 g/dL should receive RBC transfusions, while
recommending that transfusions are rarely indicated in
patients with mild anemia (Hb[10 g/dL) [7]. The Naga-
saki group Found that there is a great variation around the
world in the Hb threshold that is used to initiate RBC
transfusions: in Asia-Paciﬁc, the range of the threshold
level is 6–9 g/dL, while in Europe it is 8–10 g/dL, and 7–
10 g/dL in Latin America [11]. The UK MDS group
guidelines do not suggest a Hb concentration below which
transfusions should be initiated, recommending that each
individual case needs to be considered separately; however,
they note that transfusions should be considered in any
patient with symptoms of anemia, and that supportive care
is particularly important for patients with good-prognosis
MDS and for those with a poor prognosis whose age or
performance status precludes them from receiving more
intensive forms of therapy [8].
3.3 Management of iron overload
Although RBC transfusions remain an integral part of the
management of MDS, chronic transfusions result in iron
overload from catabolism of transfused erythrocytes and
from plasma iron levels exceeding the binding capacity of
transferrin. Iron overload can cause signiﬁcant damage of
the heart, liver and endocrine glands [17]. All the guide-
lines recommend that iron overload should be treated with
iron chelation therapy to achieve a safe iron concentration
in tissues and plasma. Likewise, they all recommend that
the patients who are most likely to beneﬁt from iron che-
lation therapy are those who are of low risk (e.g., low or
Int-1; RA, RARS or 5q-MDS), and those who will continue
to receive long-term RBC transfusions. The Japanese group
of physicians meeting in Florence established that there is
an issue with iron overload in a wider range of bone-
marrow failure syndromes and within those categories set
out the criteria for identifying patients who need iron
chelation therapy. These recommendations are discussed in
further detail in the accompanying manuscript by Dr
Ozawa.
The NCCN guidelines recommend that although moni-
toring of serum ferritin levels is a useful method, it is less
precise than superconducting quantum interference device
(SQUID) or hepatic magnetic resonance imaging (MRI) [9].
The guidelines mostly recommend iron chelation ther-
apy with deferoxamine (DFO, Desferal
). The UK
guidelines recommend that audiometry and ophthalmology
should be reviewed prior to DFO therapy and repeated at
least annually, and that vitamin C (100–200 mg daily)
should be commenced after 1 month of DFO therapy [8].
The Nagasaki group developed their guidelines prior to
widespread use of the once-daily oral chelator, deferasirox
(Exjade
). These experts based their consensus on
knowledge at the time, rather than possible future devel-
opments; however, the guidelines explain that a suitable
oral chelator would potentially overcome many of the
problems associated with administration of subcutaneous
infusions of DFO [11].
Based on the summary presented at the MDS congress in
Florence, Italy, in May 2007, it is expected that the MDS
Foundation guidelines will recommend that iron chelation
therapy should be initiated when a patient’s serum ferritin
reaches1,000 lg/L,and/orafterthepatienthasreceivedtwo
units of RBCs/month for at least 1 year. It was agreed that
serumferritinlevelsshouldnotbetheonlyfactortoconsider
as patients can present with elevated serum ferritin levels as
a result of ineffective erythropoiesis or due to inﬂammatory
conditions.Ironchelationtherapywasdiscussed,andshould
be offered to patients with an anticipated survival of greater
than 1 year, and the choice of chelator should be left to the
discretionofthephysician.Toensurethatthegoaloftherapy
is attained, serum ferritin levels should be monitored at least
every 3 months during therapy [10].
Table 2 summarizes the recommendations from each set
of guidelines for the initiation of iron chelation therapy
based on transfusion status, target serum ferritin level and
MDS risk score. The table also indicates which iron che-
lation therapy that each set of guidelines recommends, the
target serum ferritin level and techniques for monitoring
iron chelation therapy.
4 Conclusions
The classiﬁcation and scoring systems that have been
devised provide a clearer understanding of the
Overview of iron chelation therapy guidelines 27
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123heterogeneous MDS diseases and an insight into how to use
risk-adapted treatment approaches for MDS. Recent
developments in the treatment of MDS allow clinicians to
treat patients with a range of new therapies. This has
necessitated the development of guidelines to steer
healthcare professionals within each region to the available
treatments and how to apply these to a complex disease.
The guidelines all concur that RBC transfusions are
clinically beneﬁcial to treat the symptomatic anemia in
MDS, but caution that iron overload needs to be adequately
managed to avoid the clinical consequences of organ
damage. The guidelines agree that patients with low-risk
MDS receiving RBC transfusions are the most likely to
beneﬁt from iron chelation therapy, but differ in their
recommendations for when iron chelation therapy should
be initiated. The guidelines also differ on the appropriate
target serum ferritin level that should be reached to manage
iron overload adequately; overall, however, they favor
maintaining serum ferritin at \1,000 lg/L. Most of the
guidelines recommend DFO for iron chelation, and the
Nagasaki guidelines suggest that an oral chelator would be
very useful. The NCCN guidelines, revised annually, rec-
ommend DFO or deferasirox, also noting that an oral iron
chelator would more readily treat iron overload. The Italian
and UK guidelines also recommend DFO, and were pub-
lished prior to the approval of deferasirox in Europe.
Research continues into new approaches for the man-
agement of MDS, and there have been a number of
developments in the ﬁeld since publication of the ﬁrst
guidelines. More data are now available regarding the
impact of iron overload in MDS and have prompted the
development of more recent guidelines speciﬁc to this.
These will undoubtedly be reviewed and updated as clini-
cal experience in the management of iron overload grows.
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